Treatment of Non-Cardiac Chest Pain

Disease-a-Month

Volumn 54, Issue 9, 2008, Pages 642-670

  Achem, Sami R ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ARGININE; BOTULINUM TOXIN A; CIMETIDINE; CIMETROPIUM; CITALOPRAM; CLOMIPRAMINE; CLONIDINE; DESIPRAMINE; DILTIAZEM; ESOMEPRAZOLE; GLYCERYL TRINITRATE; HISTAMINE H2 RECEPTOR ANTAGONIST; IMIPRAMINE; ISOSORBIDE DINITRATE; LANSOPRAZOLE; NIFEDIPINE; NITRATE; OMEPRAZOLE; PAROXETINE; PROTON PUMP INHIBITOR; RABEPRAZOLE; RANITIDINE; SERTRALINE; SILDENAFIL; TEGASEROD; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VERAPAMIL;

ANTIREFLUX OPERATION; CLINICAL TRIAL; COGNITIVE THERAPY; COMBINATION CHEMOTHERAPY; CONSTIPATION; COST BENEFIT ANALYSIS; DIAGNOSTIC TEST; DISEASE ASSOCIATION; DROWSINESS; DRUG DOSE TITRATION; DRUG EFFECT; DRUG MEGADOSE; EDEMA; EJACULATION DISORDER; ENDOSCOPY; ESOPHAGUS FUNCTION DISORDER; GASTROESOPHAGEAL REFLUX; HEADACHE; HEALTH CARE COST; HEART ARRHYTHMIA; HUMAN; HYPERALGESIA; HYPOTENSION; INTRAOCULAR PRESSURE; LIBIDO DISORDER; LOW DRUG DOSE; NONCARDIAC CHEST PAIN; POSTOPERATIVE COMPLICATION; PRIAPISM; PSYCHOTHERAPY; RESTLESSNESS; REVIEW; SIDE EFFECT; TACHYCARDIA; TRANSCUTANEOUS NERVE STIMULATION; TREATMENT OUTCOME; TREATMENT RESPONSE; URINE RETENTION; XEROSTOMIA;

ANTI-ULCER AGENTS; BOTULINUM TOXIN TYPE A; CALCIUM CHANNEL BLOCKERS; CHEST PAIN; DILTIAZEM; ENZYME INHIBITORS; ESOPHAGEAL MOTILITY DISORDERS; ESOPHAGEAL SPASM, DIFFUSE; GASTROESOPHAGEAL REFLUX; HYPERALGESIA; NEUROMUSCULAR AGENTS; NIFEDIPINE; NITRATES; OMEPRAZOLE; RANITIDINE; TRANSCUTANEOUS ELECTRIC NERVE STIMULATION;

EID: 49749088921     PISSN: 00115029     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.disamonth.2008.06.008     Document Type: Review

References (121)

1. DeMeester T.R., O'Sullivan G.C., Bermudez G., et al. Esophageal function in patients with angina-type chest pain and normal coronary angiograms. Ann Surg 196 4 (1982) 488-498
2. Achem S.R., Kolts B.E., Wears R., et al. Chest pain associated with nutcracker esophagus: a preliminary study of the role of gastroesophageal reflux. Am J Gastroenterol 88 2 (1993) 187-192
3. Stahl W.G., Beton R.R., Johnson C.S., et al. Diagnosis and treatment of patients with gastroesophageal reflux and noncardiac chest pain. South Med J 87 7 (1994) 739-742
4. Achem S.R., Kolts B.E., MacMath T., et al. Effects of omeprazole versus placebo in treatment of noncardiac chest pain and gastroesophageal reflux. Dig Dis Sci 42 10 (1997) 2138-2145
5. Chambers J., Cooke R., Anggiansah A., et al. Effect of omeprazole in patients with chest pain and normal coronary anatomy: initial experience. Int J Cardiol 65 1 (1998) 51-55
6. Flook N., Moayyedi P., Dent J., et al. Esomeprazole for treatment of unexplained chest pain in primary care: a prospective, randomized, double-blid, placebo-controlled multicenter study. Gastroenetrology 132 4 (2007) T1163 (suppl 2)
7. Fass R., Fennerty M.B., Johnson C., et al. Correlation of ambulatory 24-hour esophageal pH monitoring results with symptom improvement in patients with noncardiac chest pain due to gastroesophageal reflux disease. J Clin Gastroenterol 28 1 (1999) 36-39
8. Wong W.M., Beeler J., Risner-Adler S., et al. Attitudes and referral patterns of primary care physicians when evaluating subjects with noncardiac chest pain-a national survey. Dig Dis Sci 50 4 (2005) 656-661
9. Achem S., Ferguson D., Hugl B., et al. Persistent noncardiac chest pain in patients on PPI therapy: prevalence, prescribing patterns and results of pH testing at a tertiary referral center (Abstract 48). Am J Gastroenterol 100 9 (2005) S38 (suppl)
10. Wong W., and Fass R. The proton pump inhibitor (PPI) therapeutic trial. In: Fass R., and Eslick G. (Eds). Noncardiac Chest Pain: A Growing Medical Problem (2007), Plural Publish, San Diego, CA 103-118
11. Young M.A., Sanowski R., Talbert G., et al. Omeprazole administration as a test for gastroesophageal reflux (abstract). Gastroenetrology 102 (1992) 192
12. Squillance S., Young M.A., and Sanowski R. Single dose omeprazole as a test for noncaradiac chest pain (abstract). Gastroenetrology 107 (1993) A197
13. Fass R., Fennerty M.B., Ofman J.J., et al. The clinical and economic value of a short course of omeprazole in patients with noncardiac chest pain. Gastroenterology 115 1 (1998) 42-49
14. Pandak W.M., Arezo S., Everett S., et al. Short course of omeprazole: a better first diagnostic approach to noncardiac chest pain than endoscopy, manometry, or 24-hour esophageal pH monitoring. J Clin Gastroenterol 35 4 (2002) 307-314
15. Xia H.H., Lai K.C., Lam S.K., et al. Symptomatic response to lansoprazole predicts abnormal acid reflux in endoscopy-negative patients with non-cardiac chest pain. Aliment Pharmacol Ther 17 3 (2003) 369-377
16. Bautista J., Fullerton H., Briseno M., et al. The effect of an empirical trial of high-dose lansoprazole on symptom response of patients with non-cardiac chest pain: a randomized, double-blind, placebo-controlled, crossover trial. Aliment Pharmacol Ther 19 10 (2004) 1123-1130
17. Dickman R., Emmons S., Cui H., et al. The effect of a therapeutic trial of high-dose rabeprazole on symptom response of patients with non-cardiac chest pain: a randomized, double-blind, placebo-controlled, crossover trial. Aliment Pharmacol Ther 22 6 (2005) 547-555
18. Ofman J.J., Gralnek I.M., Udani J., et al. The cost-effectiveness of the omeprazole test in patients with noncardiac chest pain. Am J Med 107 3 (1999) 219-227
19. Borzecki A.M., Pedrosa M.C., and Prashker M.J. Should noncardiac chest pain be treated empirically?. A cost-effectiveness analysis. Arch Intern Med 160 6 (2000) 844-852
20. Cremonini F., Wise J., Moayyedi P., et al. Diagnostic and therapeutic use of proton pump inhibitors in non-cardiac chest pain: a metaanalysis. Am J Gastroenterol 100 6 (2005) 1226-1232
21. Wang W.H., Huang J.Q., Zheng G.F., et al. Is proton pump inhibitor testing an effective approach to diagnose gastroesophageal reflux disease in patients with noncardiac chest pain?. A meta-analysis. Arch Intern Med 165 11 (2005) 1222-1228
22. Schwartz M.P., Wellink H., Gooszen H.G., et al. Endoscopic gastroplication for the treatment of gastro-oesophageal reflux disease: a randomised, sham-controlled trial. Gut 56 1 (2007) 20-28
23. Annese V., Caletti G., Cipolletta L., et al. Endoscopic treatment of gastroesophageal reflux disease. Endoscopy 37 5 (2005) 470-478
24. Liu J.J., Carr-Locke D.L., Osterman M.T., et al. Endoscopic treatment for atypical manifestations of gastroesophageal reflux disease. Am J Gastroenterol 101 3 (2006) 440-445
25. Lundell L., Miettinen P., Myrvold H.E., et al. Continued (5-year) followup of a randomized clinical study comparing antireflux surgery and omeprazole in gastroesophageal reflux disease. J Am Coll Surg 192 2 (2001) 172-179 discussion 179-81
26. Lundell L., Miettinen P., Myrvold H.E., et al. Long-term management of gastro-oesophageal reflux disease with omeprazole or open antireflux surgery: results of a prospective, randomized clinical trial. The Nordic GORD Study Group. Eur J Gastroenterol Hepatol 12 8 (2000) 879-887
27. Bammer T., Freeman M., Shahriari A., et al. Outcome of laparoscopic antireflux surgery in patients with nonerosive reflux disease. J Gastrointest Surg 6 5 (2002) 730-737
28. So J.B., Zeitels S.M., and Rattner D.W. Outcomes of atypical symptoms attributed to gastroesophageal reflux treated by laparoscopic fundoplication. Surgery 124 1 (1998) 28-32
29. Chen R.Y., and Thomas R.J. Results of laparoscopic fundoplication where atypical symptoms coexist with oesophageal reflux. Aust N Z J Surg 70 12 (2000) 840-842
30. Farrell T.M., Richardson W.S., Trus T.L., et al. Response of atypical symptoms of gastro-oesophageal reflux to antireflux surgery. Br J Surg 88 12 (2001) 1649-1652
31. Patti M.G., Molena D., Fisichella P.M., et al. Gastroesophageal reflux disease (GERD) and chest pain. Results of laparoscopic antireflux surgery. Surg Endosc 16 4 (2002) 563-566
32. Rakita S., Villadolid D., Thomas A., et al. Laparoscopic Nissen fundoplication offers high patient satisfaction with relief of extraesophageal symptoms of gastroesophageal reflux disease. Am Surg 72 3 (2006) 207-212
33. Katz P.O., Dalton C.B., Richter J.E., et al. Esophageal testing of patients with noncardiac chest pain or dysphagia. Results of three years' experience with 1161 patients. Ann Intern Med 106 4 (1987) 593-597
34. Dekel R., Pearson T., Wendel C., et al. Assessment of oesophageal motor function in patients with dysphagia or chest pain: the Clinical Outcomes Research Initiative experience. Aliment Pharmacol Ther 18 11-12 (2003) 1083-1089
35. Achem S.R., and Benjamin S. Esophageal dysmotility (spastic dysmotility). In: Castell D.O. (Ed). The Esophagus. (2nd edition) (1995), Little, Brown and Co, Boston, MA 247-268
36. Richter J.E., Dalton C.B., Bradley L.A., et al. Oral nifedipine in the treatment of noncardiac chest pain in patients with the nutcracker esophagus. Gastroenterology 93 1 (1987) 21-28
37. Achem S.R. Treatment of spastic esophageal motility disorders. Gastroenterol Clin North Am 33 1 (2004) 107-124
38. Crozier R.E., Glick M.E., Gibb S.P., et al. Acid-provoked esophageal spasm as a cause of noncardiac chest pain. Am J Gastroenterol 86 11 (1991) 1576-1580
39. Swamy N. Esophageal spasm: clinical and manometric response to nitroglycerine and long acting nitrites. Gastroenterology 72 1 (1977) 23-27
40. Pehlivanov N., Liu J., and Mittal R.K. Sustained esophageal contraction: a motor correlate of heartburn symptom. Am J Physiol Gastrointest Liver Physiol 281 3 (2001) G743-G751
41. Almansa C., Wolfsen H., DeVault K., et al. Diffuse esophageal spasm: idiopathic or reflux related? (abstract). Gastroenetrology (2008) in press
42. Hughes J., Lockhart J., and Joyce A. Do calcium antagonists contribute to gastro-oesophageal reflux disease and concomitant noncardiac chest pain?. Br J Clin Pharmacol 64 1 (2007) 83-89
43. Bortolotti M., Labriola E., Bacchelli S., et al. "Oesophageal angina" in patients with angina pectoris: a possible side effect of chronic therapy with nitroderivates and Ca-antagonists. Ital J Gastroenterol 24 7 (1992) 405-408
44. Storr M., Allescher H.D., and Classen M. Current concepts on pathophysiology, diagnosis and treatment of diffuse oesophageal spasm. Drugs 61 5 (2001) 579-591
45. Orlando R.C., and Bozymski E.M. Clinical and manometric effects of nitroglycerin in diffuse esophageal spasm. N Engl J Med 289 1 (1973) 23-25
46. Shafran I., Ellison E.C., Fromkes J.J., et al. Segmental esophageal spasm: a variant of diffuse esophageal spasm. Gastroenterology 44 (1979) 49
47. Parker W.A., and MacKinnon G.L. Nitrites in the treatment of diffuse esophageal spasm. Drug Intell Clin Pharm 15 10 (1981) 806-807
48. Mellow M.H. Effect of isosorbide and hydralazine in painful primary esophageal motility disorders. Gastroenterology 83 2 (1982) 364-370
49. Millaire A., Ducloux G., Marquand A., et al. Nitroglycerin and angina with angiographically normal coronary vessels. Clinical effects and effects on esophageal motility. Arch Mal Coeur Vaiss 82 1 (1989) 63-68
50. Konturek J.W., Gillessen A., and Domschke W. Diffuse esophageal spasm: a malfunction that involves nitric oxide?. Scand J Gastroenterol 30 11 (1995) 1041-1045
51. Preiksaitis H.G., Tremblay L., and Diamant N.E. Nitric oxide mediates inhibitory nerve effects in human esophagus and lower esophageal sphincter. Dig Dis Sci 39 4 (1994) 770-775
52. Anand N., and Paterson W.G. Role of nitric oxide in esophageal peristalsis. Am J Physiol 266 1 (1994) G123-G131
53. Murray J.A., Ledlow A., Launspach J., et al. The effects of recombinant human hemoglobin on esophageal motor functions in humans. Gastroenterology 109 4 (1995) 1241-1248
54. Konturek J.W., Thor P., Lukaszyk A., et al. Endogenous nitric oxide in the control of esophageal motility in humans. J Physiol Pharmacol 48 2 (1997) 201-209
55. Boger R.H., and Bode-Boger S.M. The clinical pharmacology of L-arginine. Annu Rev Pharmacol Toxicol 41 (2001) 79-99
56. Bortolotti M., Brunelli F., Sarti P., et al. Clinical and manometric effects of L-arginine in patients with chest pain and oesophageal motor disorders. Ital J Gastroenterol Hepatol 29 4 (1997) 320-324
57. Bortolotti M., Mari C., Giovannini M., et al. Effects of sildenafil on esophageal motility of normal subjects. Dig Dis Sci 46 11 (2001) 2301-2306
58. Kim H.S., Conklin J.L., and Park H. The effect of sildenafil on segmental oesophageal motility and gastro-oesophageal reflux. Aliment Pharmacol Ther 24 7 (2006) 1029-1036
59. Rhee P.L., Hyun J.G., Lee J.H., et al. The effect of sildenafil on lower esophageal sphincter and body motility in normal male adults. Am J Gastroenterol 96 12 (2001) 3251-3257
60. Eherer A.J., Schwetz I., Hammer H.F., et al. Effect of sildenafil on oesophageal motor function in healthy subjects and patients with oesophageal motor disorders. Gut 50 6 (2002) 758-764
61. Agrawal A., Tutuian R., Hila A., et al. Successful use of phosphodiesterase type 5 inhibitors to control symptomatic esophageal hypercontractility: a case report. Dig Dis Sci 50 11 (2005) 2059-2062
62. Bortolotti M., Pandolfo N., Giovannini M., et al. Effect of Sildenafil on hypertensive lower oesophageal sphincter. Eur J Clin Invest 32 9 (2002) 682-685
63. Bassotti G., Gaburri M., Imbimbo B.P., et al. Manometric evaluation of cimetropium bromide activity in patients with the nutcracker oesophagus. Scand J Gastroenterol 23 9 (1988) 1079-1084
64. Traube M., and McCallum R.W. Calcium-channel blockers and the gastrointestinal tract. American College of Gastroenterology's Committee on FDA related matters. Am J Gastroenterol 79 11 (1984) 892-896
65. Cohen S., and Green F. The mechanics of esophageal muscle contraction. Evidence of an inotropic effect of gastrin. J Clin Invest 52 8 (1973) 2029-2040
66. de Carle D.J., Christensen J., Szabo A.C., et al. Calcium dependence of neuromuscular events in esophageal smooth muscle of the opossum. Am J Physiol 232 6 (1977) E547-E552
67. Blackwell J.N., Holt S., and Heading R.C. Effect of nifedipine on oesophageal motility and gastric emptying. Digestion 21 1 (1981) 50-56
68. Davies H.A., Lewis M., Rhodes J., et al. Nifedipine for relief of esophageal chest pain?. N Engl J Med 307 20 (1982) 1274
69. Nasrallah S.M. Nifedipine in the treatment of diffuse oesophageal spasm. Lancet 2 8310 (1982) 1285
70. Nasrallah S.M., Tommaso C.L., Singleton R.T., et al. Primary esophageal motor disorders: clinical response to nifedipine. South Med J 78 3 (1985) 312-315
71. Thomas E., Witt P., Willis M., et al. Nifedipine therapy for diffuse esophageal spasm. South Med J 79 7 (1986) 847-849
72. Davies H.A., Lewis M.J., Rhodes J., et al. Trial of nifedipine for prevention of oesophageal spasm. Digestion 36 2 (1987) 81-83
73. Banciu T., Iova M., Biroasiu G., et al. The diagnostic and therapeutic contribution of calcium channel inhibitors (nifedipine) in esophageal spasm. Med Interne 28 1 (1990) 69-71
74. Traube M., Hongo M., Magyar L., et al. Effects of nifedipine in achalasia and in patients with high-amplitude peristaltic esophageal contractions. JAMA 252 13 (1984) 1733-1736
75. Richter J.E., Spurling T.J., Cordova C.M., et al. Effects of oral calcium blocker, diltiazem, on esophageal contractions. Studies in volunteers and patients with nutcracker esophagus. Dig Dis Sci 29 7 (1984) 649-656
76. Cattau Jr. E.L., Castell D.O., Johnson D.A., et al. Diltiazem therapy for symptoms associated with nutcracker esophagus. Am J Gastroenterol 86 3 (1991) 272-276
77. Drenth J.P., Bos L.P., and Engels L.G. Efficacy of diltiazem in the treatment of diffuse oesophageal spasm. Aliment Pharmacol Ther 4 4 (1990) 411-416
78. Goyal R.K., and Rattan S. Effects of sodium nitroprusside and verapamil on lower esophageal sphincter. Am J Physiol 238 1 (1980) G40-G44
79. Richter J.E., Sinar D.R., Cordova C.M., et al. Verapamil: a potent inhibitor of esophageal contractions in the baboon. Gastroenterology 82 5 (1982) 882-886
80. Allen M., Mellow M., Robinson M.G., et al. Comparison of calcium channel blocking agents and an anticholinergic agent on oesophageal function. Aliment Pharmacol Ther 1 2 (1987) 153-159
81. Bromm B., Meier W., and Scharein E. Imipramine reduces experimental pain. Pain 25 2 (1986) 245-257
82. Peghini P.L., Katz P.O., and Castell D.O. Imipramine decreases oesophageal pain perception in human male volunteers. Gut 42 6 (1998) 807-813
83. Millan M.J. Descending control of pain. Prog Neurobiol 66 6 (2002) 355-474
84. Kranzler J.D., Gendreau J.F., and Rao S.G. The psychopharmacology of fibromyalgia: a drug development perspective. Psychopharmacol Bull 36 1 (2002) 165-213
85. Lawson K. Tricyclic antidepressants and fibromyalgia: what is the mechanism of action?. Expert Opin Investig Drugs 11 10 (2002) 1437-1445
86. Clouse R.E., Lustman P.J., Eckert T.C., et al. Low-dose trazodone for symptomatic patients with esophageal contraction abnormalities. A double-blind, placebo-controlled trial. Gastroenterology 92 4 (1987) 1027-1036
87. Prakash C., and Clouse R.E. Long-term outcome from tricyclic antidepressant treatment of functional chest pain. Dig Dis Sci 44 12 (1999) 2373-2379
88. Cannon III R.O., Quyyumi A.A., Mincemoyer R., et al. Imipramine in patients with chest pain despite normal coronary angiograms. N Engl J Med 330 20 (1994) 1411-1417
89. Handa M., Mine K., Yamamoto H., et al. Antidepressant treatment of patients with diffuse esophageal spasm: a psychosomatic approach. J Clin Gastroenterol 28 3 (1999) 228-232
90. Clouse R.E. Pyschotrophic medications for the treatment of functional gastrointestinal disorders. Clin Perspect Gastroenterol 2 (1999) 348-356
91. Varia I., Logue E., O'Connor C., et al. Randomized trial of sertraline in patients with unexplained chest pain of noncardiac origin. Am Heart J 140 3 (2000) 367-372
92. Broekaert D., Fischler B., Sifrim D., et al. Influence of citalopram, a selective serotonin reuptake inhibitor, on oesophageal hypersensitivity: a double-blind, placebo-controlled study. Aliment Pharmacol Ther 23 3 (2006) 365-370
93. Rodriguez-Stanley S., Zubaidi S., Proskin H.M., et al. Effect of tegaserod on esophageal pain threshold, regurgitation, and symptom relief in patients with functional heartburn and mechanical sensitivity. Clin Gastroenterol Hepatol 4 4 (2006) 442-450
94. Doraiswamy P.M., Varia I., Hellegers C., et al. A randomized controlled trial of paroxetine for noncardiac chest pain. Psychopharmacol Bull 39 1 (2006) 15-24
95. Achem S.R. Chest pain and serotonin: a possible link?. Gastroenterology 121 2 (2001) 495-496
96. Birgisson S., and Richter J.E. Achalasia: what's new in diagnosis and treatment?. Dig Dis 15 suppl 1 (1997) 1-27
97. Miller L.S., Parkman H.P., Schiano T.D., et al. Treatment of symptomatic nonachalasia esophageal motor disorders with botulinum toxin injection at the lower esophageal sphincter. Dig Dis Sci 41 10 (1996) 2025-2031
98. Miller L.S., Pullela S.V., Parkman H.P., et al. Treatment of chest pain in patients with noncardiac, nonreflux, nonachalasia spastic esophageal motor disorders using botulinum toxin injection into the gastroesophageal. Am J Gastroenterol 97 7 (2002) 1640-1646
99. Storr M., Allescher H.D., Rosch T., et al. Treatment of symptomatic diffuse esophageal spasm by endoscopic injections of botulinum toxin: a prospective study with long-term follow-up. Gastrointest Endosc 54 6 (2001) 754-759
100. Nebendahl J.C., Brand B., von Schrenck T., et al. Treatment of diffuse esophageal spasm with botulinum toxin: a prospective study with 6 months' follow up. Gastrointest Endosc 49 4 (1999) A302
101. Cassidy M.J., Schiano T.D., Adrain A.L., et al. Botulinum toxin injection for the treatment of symptomatic diffuse esophageal spasm. Am J Gastroenterol 91 9 (1996) A11.P1884
102. Lacy B.E., Zayat E.N., and Crowell M.D. Case report: botulinum toxin in hypertensive lower esophageal sphincter: a manometric case study. Dysphagia 17 1 (2002) 75-80
103. Jones M.P. Botulinum toxin in hypertensive lower esophageal sphincter [Letter]. Am J Gastroenterol 91 6 (1996) 1283-1284
104. Johnson M.I., Ashton C.H., and Thompson J.W. An in-depth study of long-term users of transcutaneous electrical nerve stimulation (TENS). Implications for clinical use of TENS. Pain 44 3 (1991) 221-229
105. Borjesson M., Pilhall M., Eliasson T., et al. Esophageal visceral pain sensitivity: effects of TENS and correlation with manometric findings. Dig Dis Sci 43 8 (1998) 1621-1628
106. Jones H., Cooper P., Miller V., et al. Treatment of non-cardiac chest pain: a controlled trial of hypnotherapy. Gut 55 10 (2006) 1403-1408
107. Eslick G.D., Jones M.P., and Talley N.J. Non-cardiac chest pain: prevalence, risk factors, impact and consulting: a population-based study. Aliment Pharmacol Ther 17 9 (2003) 1115-1124
108. Wong W.M., Lam K.F., Cheng C., et al. Population based study of noncardiac chest pain in southern Chinese: prevalence, psychosocial factors and health care utilization. World J Gastroenterol 10 5 (2004) 707-712
109. van Peski-Oosterbaan A.S., Spinhoven P., van der Does A.J., et al. Noncardiac chest pain: interest in a medical psychological treatment. J Psychosom Res 45 5 (1998) 471-476
110. van Peski-Oosterbaan A.S., Spinhoven P., van Rood Y., et al. Cognitive-behavioral therapy for noncardiac chest pain: a randomized trial. Am J Med 106 4 (1999) 424-429
111. Klimes I., Mayou R.A., Pearce M.J., et al. Psychological treatment for atypical non-cardiac chest pain: a controlled evaluation. Psychol Med 20 3 (1990) 605-611
112. Kisely S., Campbell L.A., and Skerritt P. Psychological interventions for symptomatic management of non-specific chest pain in patients with normal coronary anatomy. Cochrane Database Syst Rev 1 (2005) CD004101
113. Esler J.L., and Bock B.C. Psychological treatments for noncardiac chest pain: recommendations for a new approach. J Psychosom Res 56 3 (2004) 263-269
114. Huffman J.C., and Stern T.A. The use of benzodiazepines in the treatment of chest pain: a review of the literature. J Emerg Med 25 4 (2003) 427-437
115. Beitman B.D., Basha I.M., Trombka L.H., et al. Pharmacotherapeutic treatment of panic disorder in patients presenting with chest pain. J Fam Pract 28 2 (1989) 177-180
116. Beitman B.D., Basha I.M., Trombka L.H., et al. Alprazolam in the treatment of cardiology patients with atypical chest pain and panic disorder. J Clin Psychopharmacol 8 2 (1988) 127-130
117. Wulsin L.R., Maddock R., Beitman B., et al. Clonazepam treatment of panic disorder in patients with recurrent chest pain and normal coronary arteries. Int J Psychiatry Med 29 1 (1999) 97-105
118. Johansson B., Halldner L., Dunwiddie T.V., et al. Hyperalgesia, anxiety, and decreased hypoxic neuroprotection in mice lacking the adenosine A1 receptor. Proc Natl Acad Sci U S A 98 16 (2001) 9407-9412
119. Sylven C., Beermann B., Jonzon B., et al. Angina pectoris-like pain provoked by intravenous adenosine in healthy volunteers. Br Med J (Clin Res Ed) 293 6541 (1986) 227-230
120. Rao S.S., Mudipalli R.S., Remes-Troche J.M., et al. Theophylline improves esophageal chest pain: a randomized, placebo-controlled study. Am J Gastroenterol 102 5 (2007) 930-938
121. Achem S.R. New frontiers for the treatment of noncardiac chest pain: the adenosine receptors. Am J Gastroenterol 102 5 (2007) 939-941